AnaptysBio Posts Earnings Beat, Exceeds Estimates by $0.69 EPS

The biotech firm reported strong quarterly results, with revenue and earnings surpassing analyst forecasts.

Mar. 3, 2026 at 10:10pm

Got story updates? Submit your updates here. ›

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company, announced its quarterly earnings results on Tuesday. The company reported earnings per share of $1.58, exceeding the consensus estimate of $0.89 by $0.69. AnaptysBio also generated revenue of $108.25 million during the quarter, compared to analyst expectations of $87.09 million.

Why it matters

AnaptysBio's better-than-expected financial performance highlights the progress the company is making in advancing its pipeline of immunology and inflammation-focused therapeutic antibodies. The earnings beat and revenue surge suggest the company's drug candidates are gaining traction, which could bode well for future growth and development.

The details

The biotechnology company reported a negative net margin of 49.94% and a negative return on equity of 1,101.24% for the quarter. AnaptysBio's stock price fell $2.08, or 3.9%, to $52.83 on Tuesday following the earnings release.

  • AnaptysBio announced its quarterly earnings results on Tuesday, March 3, 2026.

The players

AnaptysBio

A clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation.

Got photos? Submit your photos here. ›

The takeaway

AnaptysBio's strong quarterly performance, with earnings and revenue exceeding analyst estimates, suggests the company's pipeline of immunology and inflammation-focused therapies is gaining momentum. This could signal positive developments for the company's future growth and drug development efforts.